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The development of retroviral vectors capable of efficient insertion of genes
into mammalian hematopoietic cells (1-7) has generated interest in gene therapy
as a potential approach for the treatment of lethal genetic disease (8, 9) . The
cloning ofa cDNA for the human adenosine deaminase enzyme (h-ADA)' (10-
12) has made the ADA deficient form of severe combined immunodeficiency
(SCID) a potential candidate for such therapy . We recently described (13) a
retroviral vector called SAX that contains the h-ADA cDNA (Fig . 1) . Using this
vector, the h-ADA gene was transferred into ADA-deficient humanT cells that
had been previously immortalized with humanT cell leukemia virus (HTLV-1) .
After gene transfer, the T cells produced the ADA enzyme from the new gene
at levels similar to those seen in normal cells. This level of expression was
sufficient to make the treated cells resistant to levels of deoxyadenosine that are
toxic to untreated ADA-deficient T cells in vitro (13) . Therefore, the SAX
retroviral vector appears to function efficiently in T cells cultured in vitro from
ADA-deficient patients .
Several groups have attempted to establish in vivo models of h-ADA gene
transfer in the mouse . Considerable success has been achieved in transferring
the h-ADA gene into murine hematopoietic cells (14), and recently expression
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'Abbreviations used in this paper.
￿
ADA, adenosine deaminase; FPLC, fast protein liquid chroma-
tography ; NPT, neomycin phosphotransferase ; SV40, simian virus 40 .
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tor. The following regions are ind
Moloney marine leukemia virus sequences; 1 .5-2.9 and 4.6-4.7 kb, neomycin-resistance gene
(neo`} from Tn 5 transposon (the hatched area is the coding sequence); 2.9-3.3 kb, Kpn I-
Hind III fragment of the SV40 early promoter; 3.3-4.6 kb, human ADA cDNA (h-ADA,
black box) ; LTR, viral long terminal repeat ; 5',5' donor splice site; V, viral packaging signal .
Restriction sites : S, Sac 1 ; K, Kpn 1 ; P, Pst 1 ; E, Eco RI ; C, Cla 1 . Scale (kb) at bottom .
of this gene has been observed in spleen foci (15), but not yet in the fully
reconstituted animal . To test the feasibility of a bone marrow transplant/gene
transfer approach in a large animal model more analogous to man, we have
ion model for the study of retrovirus-
ow cells . This report provides
expression of the h-ADA gene in
circulating hematopoictic cells in cynomolgus monkeys for short periods of time .
developed ap
mediated ADA gene trans
evidence for a low level of transfer an
sed in these studies were cynomotgus macaque
obtained from Hazelton Research Animals. NIH 3T3 cells were kindly provided
. Sandra Ruscetti (NCI, NIH) and the PG-4 cell line (used as a helper virus indicator
S'L- assays) by Dr. Robert Bassin (NCI, NIH).
for Construction .
￿
The construction of the retroviral vector SAX (Fig.
generation ofthe virus producer cell lineS3A have been described previously (13).
de by inserting simian virus 40 (SV40)-promoted human ADA cDNA into
6) parental vector, Nz . A fusion gene was created between
ral gene by placing the 400 by Kpn I-Hind III
promoter elements of the SV40 early regi
rice containing the full-length ADAcDNA (10)
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immediately upstream of a
(Eco RI-Acc I fragment of clone
Bone Marrow Processing andTransplantation,
￿
Marrow (-40-60 ml) was harvested from
the long bones of the animal before irradiation . Mononuclear cells were isolated by 3%
gelatin sedimentation and Ficoll/Hypaque gradient separation . These cells were then
incubated with vector-producing cells or vector-containing supernatants at 37'C in
presence of 8 kg/ml polybrene (Aldrich Chemical Co ., Milwaukee, WI) as described in
the text . The cynomolgus primates received a dose of 1,000 rod total body irradiation
("Co at 10 rod/min} immediately followed by infusion of their autologous bone marrow
infected with the SAX vector. This dose of irradiation produces permanent aplasi
unreconstituted animals in this primate model .
Hematopoietic Cell Culture.
￿
The CFU-C assay for myeloid progenitors has been de-
scribed (17, 18). The assay medium was McCoy's supplemented with 20% prescreened
heat-inactivated FGS (Hyclone Laboratories, Logan, UT), 10% giant cell tumor-condi-
tioned medium (Gibco, Grand Island, NY) as a source of granulocyte/macrophage colony-
stimulating factor (GM-CSF), and 0.6% agarose (Gibco) . CFU-C were allowed to grow at
37'C and were counted on day 14-17 after plating .
DNA Southern Blotting.
￿
High-molecular-weight DNA was prepared by the method of
Gross-Bellard (19) and was digested with Kpn I restriction endonuclease (New England
Biolabs, Beverly, MA), electrophoresed on a 1 .0% agarose gel (FMC Bioproducts, Rock-
land ME), and transferred to nitrocellulose (Schleicher and Schnell, Keene, NH) by theKANTOFF ET AL.
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method of Southern (20). The blot was hybridized with a s2P-labelled neo' (neomycin
resistance) gene probe (sp act >10' dpm/rig).
AdenosineDeaminase Assay.
￿
The separation of primate from human adenosine deami-
nase activity using fast protein liquid chromatography (FPLC) hasbeen described in detail
elsewhere (21). Briefly, proteins were fractionated on a Pharmacia Mono Q column (HR
5/5) using a linear gradient of 0.05-0.5 M KCI, 20 mM Tris-HC1(pH 7.5). ADA activity
in column fractions was determined by measuring the conversion of ["C]adenosine
(Amersham Corp., Arlington Heights, IL) to ["C]inosine followed by thin-layer chromat-
ographic separation using 0.1 M Na2HP0q (pH 6.8), saturated ammonium sulfate and n-
propylalcohol (100 :60:2), according to the method of Soberman and Karnovsky(22).
Neomycin Phosphotransferase (NPT)Assay.
￿
Cell lysates were made from nucleated cells
derived from Ficoll-Hypaque separation. The lysates were electrophoresed for 15 h at 50
V on a nondenaturing polyacrylamide (Pharmacia Fine Chemicals, Piscataway, NJ) gel
system and transfer of a2p from y[12P]ATP (Amersham) to a Kanamycin (Sigma Chemical
Co., St. Louis, MO) substrate was achieved using the method of Riess et al. (23) to detect
NPT activity.
In Situ Hybridization.
￿
Marrow or peripheral mononuclear hematopoietic cells, after
Ficoll-Hypaque separation, were adjusted to 2 x 10' cells/ml in Dulbecco's Minimum
Essential Medium (Biofluids, Rockville, MD) containing 10% FCS (Gibco). Cells were
transferred onto poly-L-lysine (Miles Laboratories, Naperville, IL)-coated slides by cyto-
centrifugation andfixedwith freshlymade 4% vol/volparaformaldehyde (Sigma Chemical
Co.) in PBS (Biofluids) containing 5 MM MgCl2 (Sigma Chemical Co.) for 15 min at room
temperature. The slides were stored at 4°C in 70% vol/vol ethanol/water. The methods
of hybridization, washinf and exposure of film emulsion were those of Singer et al. (24) .
Theprobe used was an
￿
S-labelled neo' probe.
TCell Cloning.
￿
T cell cloning was performed using the methods previously described
by Kernan et al. (25).
Results
Infection ofPrimate Hematopoietic Cells In Vitro.
￿
Initial studies in our primate
model were undertaken to establish whether and to what degree primate hema-
topoietic cells could be infected by the SAX vector and express the vector-
containing neo` (NPT) and h-ADA genes. Conditions were established for in
vitro analysis of infection of hematopoietic progenitor cells, based on the resis-
tance of cells expressing the neo` gene to the toxic neomycin analogue G418. As
shown in Fig. 2, the growth of normal cynomolgus marrow CFU-C (curve A) is
completely suppressed at a G418 concentration of0.29 mg/ml and above.
Two protocols for infecting bone marrow progenitor cells in vitro were used.
In the first, Ficoll/Hypaque-separated bone marrow mononuclear cells were
cocultured for various periods of time with the SAX vector-producing NIH
3T3 cell clone S3A. This producer cell line, derivedfrom the PA12 amphotropic
packaging cell line (26), generates infectious SAX virus at concentrations as high
as 6.0 X 106 neo` CFU/ml . Cocultivation of cynomolgus monkey bone marrow
mononuclear cells with an S3A monolayer for periods ranging from 4 to 24 h
conferred resistance to 1 .7 mg/ml G418 in a maximum of 7% (at 24 h) of the
CFU-C detected on day 14 (Fig. 2, curve B). In the second protocol, bone
marrow cells were exposed to virus-containing supernatants derived from the
S3A producer cells, using ratios (SAX virus/bone marrow mononuclear cells) of
between 5 and 10 to 1 . After 2 h of exposure followed by extensive washing
with PBS, >10% of day 7 CFU-C (data not shown) and 28% of the day 14 CFU-
C (Fig. 2, curve C) detected were resistant to toxic concentrations of G418.222
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FIGURE 2.
￿
Susceptibility of cynomolgus primate
myeloidprogenitors (day 14 CFU-C) to increasing
concentrations oftheneomycin analogue G418.A:
survival of control noninfected colonies. B: survival
after a 24-h cocultivation of bone marrow cells on
a monolayer of SAX-producing NIH 3T3cells. C:
survival of marrow cellsfrom animal 57 after a 2-
h incubation with a cell-free supernatant contain-
ing the SAX vector at a titer of 2 X 106 neo`
CFU/ml. Triplicates of 10' bone marrow mono-
nuclear cells per plate were used for each experi-
mental point. Thetotal number ofcolonies in the
absence of G418 was 36-58 per plate. The indi-
cated concentrations of G418 (active; dry weight
is twice as high) were added to the culture system
immediately before plating. Colonies werecounted
on day 14.
In Vivo Studies.
￿
The in vitro results outlined above were subsequently sup-
ported by the results of autologous bone marrow transplants of SAX vector-
infected bone marrow cells administered to cynomoigus monkeys. For these
experiments, 40-60 ml of heparinized bone marrow was collected from the
animal. After gel sedimentation and Ficoll/Hypaque separation to remove red
blood cells, the washed bone marrow cells were infected with the SAX vector,
either by cocultivation with S3A producer cells for 18-24 h or by incubation
with S3A-derived cell-free supernatants for 2 h. During the separation and
infectionofmarrow cells, the animals underwent total body irradiation, receiving
a midline dose of 1,000 rad. There is no animal model for ADA deficiency and,
therefore, the monkeys required lethal irradiation to ablate their remaining
marrow and make space for the treated cells. The SAX-infected bone marrow
cells were then infused back into the same animal. After transplantation, the
animals were maintained in filtered air reverse isolation, and received transfu-
sions of blood products, antibiotics, and intravenous nutritional support by an
indwelling catheter in the superior vena cava until they achieved normal hema-
topoietic function and reconstitution of all blood cell lines. At intervals after
transplantation, blood and bone marrow samples or tissues obtained at autopsy
were analyzed for vector DNA and for both h-ADA and NPT activities. The
results ofthe first six bone marrow/gene transplants are summarized in Table 1.
Cocultivation Protocol.
￿
The first two monkeys received bone marrow that had
been cocultured with a monolayer ofS3A producer cells (Table 1). One ofthese
animals (855) died of systemic bacterial infection 30 d after transplant without
evidence of recovery of normal hematopoietic function, and was not studied.
The other animal (10) experienced a rapid recovery of his white blood cells
(achieving an absolute neutrophil count of 1,000 cells/mmg by day 20), but never
achieved a normal platelet count throughout the posttransplant period (Fig. 3).
Animal 10 was sacrificed at day 69 and the tissues were analyzed for evidence ofKANTOFF ET AL.
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TABLE I
Summary ofPrimateAutologous Bone Marrow Transplantation/Gene Transfer Experiments
* Method of infection (C, coculture; S, supernatant).
$Assayedin theposttransplant period.
¢ Total h-ADA activity (at its maximum; see Fig. 6) expressed as percentage of total endogenous
primate ADA activity. The conversion of["C]adenosine to ["C]inosine reached 66% in fraction 3
of the (FPLC) fast protein liquid chromatography column shown in Fig. 5, which is the region
whereh-ADAelutes. Theendogenous monkey ADAactivity is 100% in anumber of fractions (17-
22). These values were obtained from 2-h incubations at 37°C. To determine the ratio of human
to monkey activity, each fraction in the human and monkey regions was reassayed at 1, 3, 5, 10,
30, and 60 min. The amount of ADA activity in each fraction could then be quantitated. The
percentage value shown represents 100 x (total h-ADA activity)/(total monkey endogenous ADA
activity).
A& W, aliveand well.
gene transfer. A 32P-labelled neo' gene probe was used for Southern blot analysis
of PBMC, bone marrow, and spleen DNA digested with Kpn I restriction
endonuclease. As shown in Fig. 4, a 4.9 kb Kpn I band, representing the known
unit length fragment characteristic of the intact SAX vector (see Fig. 1), was
detected in blood and marrow but not spleen. This band was also present in the
plasmid control lane, but was absent in the lane containing DNA from the PBMC
of a noninfected monkey. Analysis .of the blot suggests that the equivalent of a
single-copy of the vector sequence was present in 5-10% of blood and marrow
cells, because these bands are less than one-tenth the intensity of the plasmid
control that contained a quantity of DNA equivalent to approximately one copy
per cell. Similar results were obtained probing the same blot with a "P-labelled
h-ADA gene. However, in addition to hybridization of sequences in the bone
marrow and peripheral blood, a light band was detected at 4.9 kb in the spleen
lane (data not shown).
PBMC obtained from animal 10 on day 69 were also analyzed for h-ADA and
NPT activities. Fractionation of cell proteins by FPLC MonoQ ion-exchange
chromatography effectively separates human from primate ADA as assessed by
starch gel analysis of species specific ADA isozymes (21). In animal 10, 1 %
conversion of "C-labelled adenosine to ["C]inosine can be detected in the
fractions in which human but not monkey ADA elutes. The human ADA activity
detected was calculated to be <0.01 % of the endogenous primate ADA activity
(see legend, Table 1). NPT activity (which elutes from the column later, see Fig.
5) was also detected in the PBMC at low levels at the same time.
Supernatant Infection Protocol. In the first two transplants there was poor
recovery of bone marrow cells from the tissue culture dishes after the 24-h
Primate Mode of
infection*
Exposure
time
h
Cells Cells
infected infused
x 10'/kg x 10'/kg
NPTx h-ADA* ADA#
Endogenous Outcome
10 C 24 7.4 1.1 + + <0.01 Sacrificed day
69
855 C 24 2.0 1.0 ND ND ND Died of sepsis
day 30
56 S 2 11 .0 11 .0 + + 0.2 A&W1 >1yr
57 S 2 20.0 20.0 + + 0.5 A & W>1 yr
77 S 2 29.0 29.0 - - 0 A & W>9 mo
78 S 2 74.0 74.0 - + 0.05 A & W>9 mo224
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FIGURE 3.
￿
Hematopoietic reconstitution of primates after transplantation. A: the hemato-
poieticreconstitution of whitebloodcells(opensymbols) andplatelets(closed symbols)of primates
10 (squares) and 855 (circles), whose marrow cells were cocultivated for 24 h on a monolayer
of SAX-producing NIH 3T3 cells. After coculture, the nonadherent cells were washed with
PBS and infused back into the animal. B: the hematopoietic reconstitution of primates 56
(squares) and 57 (circles) that received autologous bone marrow cells infected during a 2-h
incubation with a cell-free supernatant containing SAX vector at a titer of 2 x 106 neo`
CFU/ml. Two additional primates described in this paper were also transplanted with a similar
protocol (Table I, primates 77 and 78); theirpattern of reconstitution wassimilar to those of
primates 56 and 57 .
cocultivation period (Table 1). In an attempt to increase the number of cells
recovered after transfer manipulations and to eliminate the possibility of S3A
cell contamination, the subsequent two vector transfers (animals 56 and 57) were
performedby incubating bone marrow cellswith afiltered (0.22 Am) supernatant
collected from the SAX vector-producing S3A cells. Infection was for 2 h, a
time that had been determined to be adequate to infect CFU-C in vitro (Fig. 2)
and to yield a good recovery ofviable bone marrow progenitor cells (Table 1).
The ratios oftotal infectious SAX virus (as measured by G418-resistant CFU/ml)
to total bone marrow cells were 8.3:1 and 4.9:1 in monkeys 56 and 57, respec-
tively. The 14-d CFU-C analysis ofan aliquot ofthe treated marrow cellsshowed
that 25% ofthe colonies were resistant to 1.7 mg/ml G418 for animal 56 (data
not shown) and 28% for animal 57 (Fig. 2, curve C). Both primates achieved a
rapid and sustained return of normal hematopoietic function with full reconsti-
tution ofall blood cell lines entirely analogous to that observed after transplants
of untreated autologous bone marrow cells. These animals survived and are
healthy more than l year after transplantation. Hematopoiesis remains normalKANTOFF ET AL .
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FIGURE 4.
￿
Southern blot of DNA extracted
fromtissuesobtainedat autopsyon day69 from
animal 10 . DNAwasprepared from spleen (S),
bone marrow (M), and blood (B). Lane 1 (-)
contains 30 ng ofDNAprepared from periph-
eral blood mononuclear cells of a control pri
mate. Lane 2 (+) contains 5 pg of the plasmid
SAX mixed with 30 ;+g control primate DNA
digested with Kpn 1 . Lanes 3 (S), 4 (M), and5
(B) contain 30 ug of DNA prepared from
spleen, bone marrow, and blood of animal 10 .
To determine if the 4.9 kb band in lanes 4 and
5might be due to contaminating plasmid DNA,
the DNA samples were reassayed, but without
Kpn I digestion . The band of positive hybridi-
zation then appeared at the origin with high-
molecular-mass DNA.
in these animals and no evidence of retroviremia has been detected by S''L-
assay .
Southern blot analyses (ofDNA extracted from PBMC obtained on days 34
and 52, as well as ofDNA from bone marrow on day 104) for evidence of SAX
vector sequences in these two animals were repeatedly negative . This suggests
that the vector, if present, was inserted in <5% of cells, that is, below the limits
of detection of the method used . PBMC were also analyzed for h-ADA activity
and for NPT activity . Both monkeys demonstrated low but readily detectable
levels of h-ADA at several times during the posttransplant course (Table 1) .
contained a level of h-ADA activity equivalent to 0.2%
of the endogenous primate activity at day 104 ; in animal 57, the peak levels of
h-ADA on day 69 brought about a 66% conversion of "C-labelled adenosine to
["C]inosine (Table I), which was calculated to be 0.5% of endogenous primate
ADA activity . The separation of human (fractions 2-4) from primate (fractions
16-25) ADA using FPLC and the levels of human and primate ADA activity
detected in animal 57 at day 69, expressed as percent adenosine to inos
conversion, are presented in the top panel of Fig . 5 . These results are contraste
with those obtained from a control animal that received uninfected autologous
bone marrow : this animal (as well as several other control animals) had no
detectable activity in the column fractions that would contain h-ADA (Fig, 5,
bottom) despite greater total protein being loaded onto the column. Sequential
assays of PBMC from animals 56 and 57 for h-ADA (Fig. 6) demonstrated h-
ADA activity between days 60 and 120 . h-ADA was no longer detectable after
day 160 in either animal . NPT activity was also detected early in the postransplant
period (day 52) but was not detected at day 104 at a time when h-ADA was still
discernible (Fig . 7).
In an attempt to determine the frequency of cells expressing the vector-
encoded RNA, in situ hybridization was performed using a "S-labelled neo'
probe on PBMC obtained from animal 57 on day 127 (Fig . 8) . Hybridizati
was detected in 28 of the 3415 (0.8%) cells counted .
To define the lineage(s) of cells containing the vector, we examined marrow226
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FIGURE 5 .
￿
FPLC fractionation of hematopoietic mononuclear cell lysates from animal 57
anda noninfected control animal .ADAactivity (bothendogenous monkey and vector-derived
human) in primate 57 bone marrow cells 69 d after transplantation is shown in the upper
panel . An uninfected control is shown in thelower panel.Thegraph represents the absorbance
at 280 nm of bone marrow cell lysate fractionated by ion-exchange chromatography on an
FPLC Mono Q column using a KCl salt gradient. Stippled bars represent ADA activity
expressed as the percent conversion of [""Cjadenosine to ["C]inosine (%A --} I) . After thin-
layer chromatographic separation ofadenosineand inosine, the raw data for fraction 3 (66%
conversion) was 9,045 cpm in the [" 4C]adenosine spot, and 17,889 cpm in the ["C]inosine
spot. Background counts were : 407 cpm for ["C]adenosine after 100% conversion (that is,
fractions 17-18), and 426 cpm for [" 4C]inosine after 0% conversion (fraction 1) . Fractions
containing humanADA, monkey ADA or neo" activity are indicated .
onable peripheral bloodT cells for evidence of G418 resistance .
Assays of marrow from both animals 57 and 58 for G418-resistant CFU-C
performed on days 28, 104, and 169 failed to demonstrate myeloid colonies
the same high concentration (1 .7 mg/ml) of G418 that was used to
-C cultured from vector-infected marrow at the time of transplanta-
ion(Fig . 2, Table II). However, with concentrations ofG418 lower than maximal
(0 .29 mg/ml), but still toxic for noninfected controls, resistant colonies were
obtained from monkey 56 at day 28 and 169 posttransplant, and from monkey
57 at day 169 posttransplant (Table II).
CFbeen used to fractionate 108
56 and 57 demonstrate the
BMT
FIGURE 6 .
￿
The h-ADA activities after FPLC fractionation detected in animals 56 and 57
over time after total body irradiation (TBI), retroviral gene transfer, and bone marrow
transplantation(BMT) . The data point at day69 foranimal 57 wastakenfrom Fig . 5, expressed
as percent conversion of f"Cladenosine to ["'C]inosine.
FIGURE 7 . The neor phosphotransfer-
ase (NPT) activity detected in animals
56 and 57 on days 52 and 104. Bone
marrow samples were taken on day 52,
and peripheral blood samples were ob-
tained on day 104 . The lanes denoted
by (+) contained lysate of 5 X 105 3T3
cells that had been infected with the N2
vector. The d52 lanes, denoted by 56
and 57, contained lysate of 10' bone
marrow cells from day 52 . The d104
lanes denoted as PB contained lysatesof
107 peripheral blood cellsand
denoted as Col. were the neor
from an FPLC MonoQcol
ig. 5) . The lanes denoted by (+)and
NPT enzyme as determined by previous
In limiting-dilution analyses of peripheral blood lymphocytes, which are
as a means of quantitating the frequency of clonableT lymphocytes expan
in the presence of mitogen (PHA) and IL-2, clonable T cells resistant to
concentrations ofU .1 mg/ml G418 were detected in animal 56 at a frequency of
1:93 on day 181 posttransplant (Fig . 9). By comparison, the overall frequency of
clonable T cells detected without selection in the PBMC from this animal was
one in seven. Thus,-8% of the clonableT cells detected in the circulation were228 RETROVIRUS-MEDIATED GENE TRANSFER IN PRIMATES
FIGURE 8 .
￿
In situ hybridization of peripheral blood from animal 57 at day 127 . Two positive
cells (one, in a cluster of negative cells in the lower left of the figure, and the other at the
upper edge on the right) showing overlying silver grains produced by hybridization of an "S-
labelled neo` probe to vector-derived mRNA are shown . There were no positive cells found
on slides made from uninfected control primate PBMC .
TABLE 11
ResistantBone Marrow Colonies (CFU-C)Assayed at Time ofInfection and after
Transplantation
Bone marrowcells were harvested, processed, and incubated with the supernatant from S3Aproducer
cells that generate viral particles (containing the SAX retroviral vector) at a titer of 2 x 106CFU/ml,
as described in the legends of Figs. 2 and 3. After infection, cells were immediately plated in
increasing concentrations o£ G418-containing CFU-C medium . For the posttransplant times, bone
marrow mononuclear cells were collected and prepared as described and directly plated into the
G418-containingCFU-C medium . The values of colonies are reported for 10 5 cells. Thenumber of
cells plated were 3 x 10 5 for the controls (G418) and 1 .2 x 10 6 for G418-containing points .
resistant to 0 .1 mg/ml G418 . In contrast, assays ofnormal cynomolgus monkey
lymphocytes have consistently failed to detect clonable T cells resistant to this
concentration (0.1 mg/ml) of G418 . Further analysis of these G418-resistant
clones for h-ADA activity and/or vector DNA sequences could not be performed
because of the limited lifetime and number of available cells .
Primate
marrow cells 0 0.29
CFU-C before
transplant
1 .71
G418
0
CFU-C
(mg/ml)
0.29
28 d
transplant
1 .71
after
0
CFU-C
0.29
169 d
transplant
1.71
after
Uninfected control 37 0 0 26 0 0 55 0 0
Monkey 56 56 17 14 153 5 0 61 1 0
Monkey 57 41 12 12 ND ND ND 53 0.6 0y
d
Z
0
c 0 ...
u-
Number of Cells Seeded Per Well
25 50 75 100
KANTOFF ET AL.
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FIGURE 9. Limiting dilution analysis of
clonable G418-resistant Tcellsfrom periph-
eral blood mononuclear cells from monkey
56 collected on day 181 after autologous
transplantation of SAX-infected marrow.
The fraction of negative wells was deter-
mined by microscopic examination on day
10 of culture. The slope of line A is the
frequency (1/7) of clonable T cells in the
absence of G418. The slopeof line B is the
frequency (1/93) of clonable T cells in the
presence of 0.1 mg/ml of G418. This con-
centration of G418 completely inhibited
growth of T cells isolated from noninfected
animals (i.e., no positive wells in four sepa-
rate control experiments).
The bone marrow cells of two additional animals, 77 and 78, were infected
with a modified protocol: the viral supernatant was at pH 7.4 rather than 6.8,
and the polybrene was mixed with the supernatantbefore additionofthemarrow
cells rather than afterwards. Although both animals reconstituted rapidly (see
Fig. 2), animal 77 showed no evidence of h-ADA activity and animal 78 had an
h-ADA level equivalent to only 0.05% ofendogenous monkey activity (Table 1).
In neither case were vector sequences or NPT activity detected. Preliminary
analysis using the modified protocol to measure gene transfer into murine CFU-
S suggests that both modifications decrease the number of spleen foci that
acquire vector DNA sequences (data not shown). Whether these modifications
can account for the primate results is still not clear.
Discussion
These studies were undertaken to establish a large animal model to evaluate
protocols that might ultimately be used for gene therapy in humans. We have
used an amphotropic retroviral vector containing the h-ADA cDNA, SAX, to
infect the marrow of cynomolgus primates for subsequent infusion back into
donor animals after total body irradiation. Our studies with primates have
demonstrated that adequate numbers of autologous bone marrow cells will
survive after in vitro culture and exposure to a retroviral vector to provide the
animal with full hematopoietic reconstitution and long-term survival. The recon-
stituted animals have also provided evidence for a low level of successful gene
transfer together with expression of the inserted genes.
As detailed in Fig. 2 and Table I, the method of infection of bone marrow230
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cells is an important variable. In previous studies with the mouse, we found that
the infection efficiency was 86% for hematopoietic progenitor cells (CFU-S)
when these cells were cocultivated with a vector-producing (namely, N2, the
parent vector of SAX) cell line (6). Accordingly, we initially used a cocultivation
protocol for our early primate transplants. Cocultivation ofprimate bone marrow
cells with the vector-producing cell line for periods of 4-24 h, however, did not
achieve as efficient a transfer into marrow progenitors as did incubation with
virus-containing supernatants. This was reflected by the consistently lower fre-
quency of G418-resistant CFU-C detected after cocultivation with the producer
cell lines. Furthermore, cocultivation with the producer line was associated with
bone marrow cell loss, and accordingly with a marked reduction in the total
number of bone marrow progenitor cells subsequently available for transplanta-
tion. This loss of cells after cocultivation is evident in the transplantation of
monkeys 10 and 855, wherein only 15-50% of cells were recovered after
cocultivation. This lower recovery ofcells undoubtedly contributed to the poor
reconstitution of hematopoietic function (particularly in platelet number)
achieved in these two monkeys. The four subsequent animals were transplanted
with bone marrow cells cultured for 2 h with virus-containing supernatant. Each
of these animals achieved full reconstitution of hematopoietic function in the
same manner observed in animals receiving autologous, unmanipulated marrow.
In vitro studies also indicated that the frequency of G418-resistant colonies
transplanted was much higher in the marrow infected with the virus-containing
supernatants. Taken together, these data suggest that short-term infection with
cell-free virus-containing supernatants provides several advantages for gene
transfer experiments in this species. However, toobtain a higher rate ofinfection,
additional modifications of the infection protocol will be necessary.
Our results demonstrate that infection and integration ofthe retroviral vector
SAX in primate marrow cells can be obtained under conditions that favor the
recovery ofviable cells, and that expression of low levels of the gene products,
both h-ADA and NPT enzymatic activities, can be detected for short periods in
circulating blood and marrow cells from some reconstituted animals. Although
the levels of expression in the PBMC and bone marrow are low, they may
represent moderate levels ofexpression on aper-cell basis. It is unfortunate that,
for logistic reasons, we do not have more complete data for animals 56 and 57
during the critical period from 60 to 120 d. The data for animal 57 are
summarized in Table III. Because the limit of resolution on our Southern blots
is ^-1 copy in 20 cells, the negative Southern blots on days 34, 52, and 104 for
animal 57 would indicate that vector DNA was present on those days in <5% of
the PBMC. The presence of neor RNA in 28 of 3,415 cells as detected by in situ
hybridization on day 127 indicates that at that time at least 0.8% of the cells
contained vector (more may have had nonexpressing vector DNA sequences).
The number ofcells containing vector on day 69, when the maximum level of
h-ADA was found (0.5% of endogenous monkey ADA activity), is unknown. If
5% of PBMC contained vector on day 69, then infected cells may produce h-
ADA at ^-10% of endogenous monkey ADA levels (in addition to endogenous
monkey ADA already being produced in the cell). If<5% of the cells containedKANTOFF ET AL.
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TABLE III
T cells**
* 14-d CFU-C; see Fig. 2 and Table II; the ± on day 169 represents a low percentage of colonies
growingat 0.29 mg/ml; see Table II. +++ means >20% G418-resistant CFU-C.
Southern blot analysis.
See Fig. 7. +++ means the activity of 105-106 positive cells.
See Figs. 5 and 6. +++ means >50% conversion of A to I; ++ means 10-50% conversion; +
means 1-10%.
See Fig. 8.
** Peripheral bloodlymphocytes were cultured that were resistant to 0.25 mg/ml G418.
vector on day 69, then the amount ofh-ADA produced on a per-cell basis could
exceed 10%.
It should be noted that vectors that do not express genes in one species may
be capable of doing so in others. We have used the SAX vector to efficiently
transfer the ADA gene into mouse hematopoieticcells but have notdetected any
ADA expression in vivo in the mouse. We are currently investigating whether
this is a vector- and/or promoter-specific phenomenon.
Our studies indicate that the expression obtained appears to be transient,
although in both animals, G418-resistant Tcells could be obtained as late as 5-
7 mo after transplant. The transient expression of vector-derived genes in blood
cells obtained from thereconstituted animals could beexplainedbyany ofseveral
possibilities. For example, infection might have been restricted to the more
differentiated bone marrow cells, which have a limited life span. Alternatively,
infection might have been achieved only in a very small number of stem cells,
with subsequent progressive dilution of these cells in the absence of a positive
selective growth advantage. It is also possible that infected cells undergo cell
membrane modification or express extraneous neoantigens that could elicit a
response from activated macrophages, NK cells, or immune lymphocytes that
are regenerating in theirradiated, marrow-reconstituted host. Finally, the decline
in h-ADA activity could be explained by the selective loss of vector sequences
due to vector instability, by a decrease in the level of expression of the vector
genes in individual cells over time, or by overproduction of ADA, thereby
inhibiting or killing positive cells.
Our failure to detect CFU-C equally G418-resistant after transplant as were
found before transplant is also consistent with any ofthe above hypotheses. The
detection of G418-resistant clonable T cells in the circulation of animal 56 at
Days after
transplant CFU-C*
Summary
DNA*
ofData on Animal
NPT§
57
ADAI In situ
0 +++
34 -
52 - +++
61 +
69 +++
104 - - ++
119 - +
127 - + +
169
230
266 - -232
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day 181 (Fig. 9) and ofTcells capable ofgrowth in G418 from animal 57 at day
230 (Table 111) also raises the possibility that long-lived T lymphocytes infected
with the SAX vector survive for extended periods in these animals.
Vector gene expression among theanimalsinourseries hasnotbeen consistent.
For example, in monkey 10, h-ADA activity was detected at levels 20-50-fold
lower than in monkeys 56 and 57, despite the fact that Southern blot analysis of
circulating cells detected vector DNA in this animal. Thus, animal 10 had a
higher proportion ofcells containing the integrated vector DNA, but expressed
the vector at a much lower level. It appears that vector expression in vivo is
dependent on variables that are not yet understood. Permanent engraftment of
cells containing an expressing gene will probably require the successful infection
ofpluripotent self-replicating stem cellsand a meansto maintain positive selective
pressure in vivo. Selective pressure may occur for hematopoietic cells containing
an expressing ADA gene in patients with ADA deficiency (8).
In conclusion, the data presented indicate that we have been able to obtain h-
ADA expression in four out of five reconstituted animals. Four of these animals
are still alive >9 mo after transplant. These animals have shown no sign of
retroviremia (S'L- assays of serum), marrow dysfunction, hematopoietic malig-
nancies, solid tumors, or other signs ofpathology. We will continue to study the
animals. The S3A cell line produces, in addition to the SAX viral particles,
^"0.1% helper virus. Whether or not this low level of helper virus affects the
infectionfrequency is not established (27). It is unlikely, however, that an ongoing
productive viral infection was established in vivo, because no evidence of retro-
viremia has been detected in any ofthe animals. Acomplementary gene transfer
program using the SAX vector into rhesus monkeys has shown low levels of h-
ADA activity (in two out of three animals) and neon activity (in one out of three
animals). In addition, these animals have shown no evidence of retroviremia or
marrow pathology. Clinicalapplication ofthis gene transfer protocol will require,
we believe, a higher and more stable level of expression of the inserted h-ADA
gene as well as greater reproducibility among animals than has been achieved to
date.
Summary
Primate bone marrow cells were infected with a retroviral vector carrying the
genes for human adenosine deaminase (h-ADA) and bacterial neomycin resis-
tance (neon). The infected cells were infused back into the lethally irradiated
donor animals. Several monkeys fully reconstituted and were shown to express
the h-ADA and neon genes at low levels in their recirculating hematopoietic cells
for short periods oftime.
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